Mounjaro® / Zepbound®
Tirzepatide is a dual GIP/GLP-1 receptor agonist for type 2 diabetes and obesity. It represents a first-in-class mechanism targeting both incretin pathways.
| Dosage Form | SC Injectable (Prefilled Pen / Autoinjector) |
| Strength | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Storage | Store at 2–8°C. After first use, store at room temperature (up to 30°C) for up to 21 days. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities.
Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Activates both incretin pathways to enhance insulin secretion, reduce glucagon, and promote weight loss.
Each Burrard Pharmaceuticals technology transfer package for Tirzepatide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.